Foghorn Therapeutics trades below net cash after Lilly’s exit, leaving investors a high-risk, preclinical pipeline option whose re-rating depends on 2027 IND progress and clinical proof-of-concept.
Overview
Foghorn Therapeutics is a clinical-stage biotech focused on chromatin-regulatory dependencies, using its Gene Traffic Control® platform to discover targeted degraders and small-molecule disruptors. Its scientific thesis addresses a sizable oncology opportunity: BAF complex mutations occur in approximately 20% of cancers, and the report estimates more than $25 billion in annual markets for EP300/CBP indications. But the October 2026 discontinuation of FHD-909 after insufficient Phase 1 efficacy, together with Lilly’s exit, leaves all active programs preclinical; key IND filings are not expected until 2027. The company is concentrating on wholly-owned EP300 and CBP degraders, ARID1B degradation, and an oral I&I candidate. FY2025 revenue was $30.9 million, while net loss was $74.3 million. Q2 2026 revenue of $16.07 million included a $14.2 million Lilly collaboration catch-up adjustment, and the company held $167.58 million in cash and securities with zero funded debt. After a 40% workforce reduction, runway extends into 2H 2029. At $1.85, shares trade below the cited $2.37 cash per diluted share, but this discount reflects substantial pipeline and financing risk. The report’s probability-weighted five-year price is $4.30; 2027 toxicology, IND, and early biological-activity milestones are the key catalysts.